36 results about "Joint disorder" patented technology

The invention provides a temporal-mandibular joint disease diagnosis method and system based on a large language model, and the method comprises the steps: collecting text data of a temporal-mandibular joint disorder syndrome, carrying out the preprocessing of the text data, obtaining a temporal-mandibular joint disease professional data set, and employing a pre-trained large language model to extract metadata; segmenting the extracted metadata into text blocks by adopting a self-adaptive semantic partitioning algorithm, and obtaining a set of the text blocks, namely a text block library; constructing a temporal-mandibular joint special disease knowledge map; according to the type of a user query statement and a knowledge graph, integrating direct semantic search and knowledge graph guide search by adopting a mixed search strategy, and performing knowledge retrieval and reasoning to obtain retrieval information; after retrieval information is input into the fine-tuned large language model, a diagnosis result is generated; according to the method, higher diagnosis accuracy can be achieved, intelligent auxiliary diagnosis of the temporomandibular joint disease can be achieved, and the accuracy and reliability of diagnosis of the temporomandibular joint disease can be improved.

The present invention provides compositions and methods for treating joint disorders characterized by inflammatory components. In certain aspects, the compositions and methods are useful for preventing the progression of and treating osteoarthritis and other arthritis in mammalian joints.

The invention belongs to the technical field of traditional Chinese medicine treatment, and discloses a method for treating knee joint diseases through a thigh medial oblique puncture method based on meridian differentiation, which comprises the following steps: step 1, performing acupuncture by adopting a 15-30-degree oblique puncture method with the height consistent with that of thigh medial muscle group fibers; 2, using a disposable sterile small needle knife with the specification of 0.5 mm * 75 mm as a needling instrument; 3, 2-3 short-range treatment cycles are set, a puncture part is positioned and disinfected firstly, and lesion areas such as medial femoral muscle deep fascia are accurately found; then a 0.5 mm * 75 mm blunt-end small needle knife is selected, and the 75 mm length can directly reach the deep lesion area of the knee joint from the inner side surface layer of the thigh. When the needle is inserted, a 15-30-degree oblique needling method is adopted, and the angle and the trend of muscle fibers on the inner side of the thigh completely go deep along muscle fiber gaps and easily penetrate into a deep layer. The 0.3 mm blunt end of the needle tip can be slightly pushed away instead of being scratched when encountering blood vessels and nerves. Finally, through 2-3 times of centralized treatment, the diseased region is stimulated for multiple times in a short time, the self-repairing ability of the body is quickly activated, adhesion tissues around the knee joint are loosened, inflammation is eliminated, blood circulation is accelerated, and actual application and operation are facilitated.

The invention relates to a composition containing a glucosamine derivative, which comprises the following components based on the total weight of the composition: 55-70 wt%, preferably 55-65 wt%, more preferably 60-65 wt% of a compound as shown in a formula (I) or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable auxiliary materials. The invention also relates to application of the compound in preparation of a medicine for preventing or treating bone or joint diseases of a subject in need of the compound.

The invention discloses a multi-level targeting composite hydrogel microsphere based on amino fullerene and an application of the multi-level targeting composite hydrogel microsphere based on amino fullerene, methylacrylate modified aldehyde hyaluronic acid is used as a matrix carrier, amino fullerene is combined with the matrix carrier, and the methylacrylate modified aldehyde hyaluronic acid-fullerene composite hydrogel microsphere is obtained. The macroscopic-cell-mitochondrial multi-layer slow-release targeting effect is achieved, ROS is remarkably reduced in vitro / in vivo, and cartilage repair is promoted. Compared with the prior art, the invention has remarkable innovativeness in targeting precision, release control and curative effect, and is suitable for precise treatment of joint diseases.

The present invention relates to compositions comprising a mixture comprising or, alternatively, consisting of a turmeric extract and at least one compound selected from the group comprising or, alternatively, consisting of cinnamon oil and thymol for use in the treatment, preventive and / or curative, of at least one joint pathology of an inflammatory and / or degenerative nature and / or of a symptom associated therewith in human beings, or monogastric animals, by modulation of the receptors and / or enzymes of the endocannabinoid system.

The present disclosure provides compositions and methods for treating and preventing localized nociception, inflammation, or morphological changes associated with joint disease or illness, back or spine conditions or disorders, and musculoskeletal diseases or dysfunction.

This application discloses compounds, compositions, and uses for the prevention or treatment of canine bone or joint diseases. The compounds are those represented by formula (A) and their pharmaceutically acceptable salts and esters, wherein R is an amino acid.

The present invention relates to a pharmaceutical composition for preventing or treating cartilage disease or inflammatory joint disease and a method for preparing a chondrospheroid having chondrocyte differentiation ability. The present invention provides a pharmaceutical composition comprising a stem cell-derived spheroid as an active ingredient for preventing or treating cartilage disease or inflammatory joint disease, and a method for preparing a chondrospheroid having chondrocyte differentiation ability, the method comprising the steps of: Inoculating stem cells into a three-dimensional (3D) cell culture vessel made of a plastic material; treating the stem cells inoculated into the 3D cell culture vessel with a chondrocyte differentiation-inducing factor; culturing the stem cells treated with the chondrocyte differentiation-inducing factor to form chondrospheroids; and separating the formed chondrospheroids.

The present invention provides a pharmaceutical composition for preventing or treating cartilage / bone / joint diseases, the pharmaceutical composition containing, as active ingredients, a substance that inhibits the signal transduction of semaphorin 4D-plexin B2, for example: a substance that inhibits the binding of plexin-B2 and semaphoring 4D; a substance that inhibits the binding of c-Met and semaphorin 4D; a substance that inhibits the binding of plexin B2 and Traf2; and a substance that inhibits the binding of plexin B2 and c-Met. In addition, the present invention provides a method for screening a drug for preventing or treating cartilage / bone / joint diseases, the method comprising a step for selecting a substance to be tested that inhibits the signal transduction of semaphorin 4D-plexin B2.

The invention relates to a preparation method of a multilayer sustained-release drug-loaded microsphere for articular cavity injection, and belongs to the field of biomedical materials and sustained-release preparations. The microsphere aims at solving the problems that traditional articular cavity lubricating gel is short in acting time and uncontrollable in drug release, and common drug-loaded microspheres are remarkable in burst release and insufficient in lubricity. The microsphere is constructed by adopting a natural material with good biocompatibility, collagen is taken as a core to load a drug, and a chitosan controlled release layer and a sodium hyaluronate lubricating layer are sequentially coated through electrostatic adsorption and covalent crosslinking to form the composite microsphere with a'core-shell-lubrication 'multilayer structure. The preparation method is based on a technical path technology of combining'crosslinking agent premixing emulsification-in-situ reaction curing 'and'layer-by-layer self-assembly-covalent crosslinking', and effective entrapment of drugs, stable construction of a controlled release structure and regulation and control of a degradation period are realized by optimizing process conditions. The microsphere can realize long-acting release of a medicine in a simulated environment, and the sodium hyaluronate on the outer layer of the microsphere material can improve the injection and pushing smoothness and is beneficial to the instant lubricity of the microsphere and retention of the microsphere in an articular cavity; all layers of materials are biodegradable, and degradation products have a potential nutrition support effect on joint tissues. The invention provides a microsphere delivery system with comprehensive performance for local treatment of joint diseases such as osteoarthritis.

This invention relates to a recombinant human secretory DDRGK1-Fc and its applications. Through experimental verification, the invention synthesizes recombinant human secretory DDRGK1-Fc, which has good bone-promoting function and is applied to the preparation of drugs for treating bone and joint-related diseases, promoting cartilage formation, and promoting intervertebral disc formation. This opens up new ideas for the treatment of bone and joint diseases and has obtained relatively solid scientific evidence.

The present invention provides a composition comprising an anionic lipid composition and a polycationic aggregating agent for use in the intra-articular treatment of a joint disease or disorder, such as osteoarthritis. In addition, a kit for preparing the composition and a novel composition comprising the anionic lipid composition and a polycationic aggregating agent are also provided.

The application discloses a functional composition, a conditioner and a use for treating or preventing bone and joint diseases. The composition of the functional composition comprises a first active component and a second active component, wherein the first active component comprises elastin peptide 1-500 mu g / mL, haematococcus pluvialis 40-20 mu g / mL, phyllanthus emblica 8-4 mu g / mL and mussel 1-500 mu g / mL in terms of concentration in the functional composition; and the second active component comprises broccoli water extract and / or boric acid substances. The application realizes the synergistic improvement of glycosaminoglycan and osteocalcin levels by scientific compounding, plays a protective role on joint, cartilage and bone health, and has natural, safe, good biocompatibility and no obvious side effects, and provides a kind of drug or a replacement scheme for bone disease treatment and prevention.

The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method and application of an amniotic fluid active complex. According to the method, inherent physical and chemical differences of different components in amniotic fluid are utilized, through a series of physical steps, the components are firstly and mildly grouped and enriched according to categories, and then the components are guided to be self-assembled again under controllable conditions to form a composite particle with a compact structure. The natural aggregation state of active ingredients in a living body before secretion or action is simulated, so that the multi-element active ingredients which naturally coexist and interact in amniotic fluid are efficiently captured and transferred as a complete functional unit, the natural ingredient spectrum is not damaged, and the original advanced structure and function are not lost. The invention provides application of an amniotic fluid active complex (RSC) in treating or preventing joint diseases or symptoms. The RSC has obvious effects in promoting cartilage matrix synthesis, inhibiting moderate and mild osteoarthritis and relieving pain.

The invention belongs to the field of biological medicines, and relates to application of induced vesicles in preparation of a medicine for treating osteoarthritis. The invention provides application of induced vesicles in preparation of medicines for treating temporomandibular joint diseases or osteoarthritis except temporomandibular joint diseases. The induced vesicles are used as medicines for treating temporomandibular joint diseases or osteoarthritis except temporomandibular joint diseases, and the effects of high safety and good effectiveness are achieved.

Provided herein is a composition comprising a population of mesenchymal stem cell (MSC) aggregates, wherein the aggregates have a mean diameter between 30 to 250 microns and number of cells per aggregate between 100 to 500 MSCs. Also provided is a method of producing said composition, and a method of obtaining conditioned medium from said aggregates. Both the composition comprising the aggregates, and the conditioned medium may be used to treat diseases, disorders, conditions or injuries such as age-related disorders, chronic and acute inflammatory conditions (including arthritis), degenerative joint diseases (including osteoarthritis), joint injury, chronic and acute respiratory diseases, musculoskeletal conditions, neurodegenerative diseases and / or brain injury.

The present invention relates to the use of a composition comprising an effective amount of oleuropein and / or its metabolites in combination with taurine and / or functional derivatives for the maintenance of joint health or the prevention or treatment of joint disorders in an individual. In particular, the present invention relates to a composition comprising an effective amount of oleuropein and / or its metabolites in combination with taurine and / or functional derivatives for use in the prevention or treatment of cartilage degeneration in an individual.

The present invention provides compositions and methods for treating joint disorders that are characterized by an inflammatory component. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint.

A glucosamine derivative-containing composition comprising, based on the total weight of the composition, 55-70 wt%, preferably 55-65 wt%, more preferably 60-65 wt% of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The present invention further relates to a use of the glucosamine derivative-containing composition in the preparation of a drug for preventing or treating bone or joint diseases of subjects in need.

1. The name of the design product: LED infrared physiotherapy lamp (vertical type). 2. The use of the design product: physiotherapy instrument for assisting in the treatment of joint diseases of the user, relieving pain, reducing inflammation, promoting wound healing, and promoting skin damage recovery. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The invention discloses a functional composition for treating or preventing bone and joint diseases, a conditioner and application. The functional composition comprises a first active component and a second active component, and according to the concentration of the functional composition, the first active component comprises 1 [mu] g / mL-500 [mu] g / mL of elastin peptide, 40 ng / mL-20 [mu] g / mL of haematococcus pluvialis, 8 ng / mL-4 [mu] g / mL of emblic leafflower fruit and 1 [mu] g / mL-500 [mu] g / mL of mussel; the second active component comprises a broccoli aqueous extract and / or boric acid substances. Through scientific compatibility, all the components synergistically improve the levels of glycosamine poly and osteocalcin, the health of joints, cartilages and bones is protected, the components are natural in source, safe, good in biocompatibility and free of obvious side effects, and a medicine or an alternative scheme thereof is provided for treatment and prevention of bone diseases.

The invention relates to the field of biological medicine, and discloses a medicine suspension composition for improving osteoarticular diseases and a preparation method thereof. In the embodiment 1, the composition comprises sterile normal saline and umbilical cord mesenchymal stem cell-loaded modified gelatin microspheres with the volume fraction of 50%; the microspheres are prepared from phenylboronic acid-sulfobetaine bifunctional modified gelatin, 0.2 M trehalose, a photoinitiator and stem cells through a microfluidic technology. The modified gelatin is grafted with 3-carboxyphenylboronic acid through an amido bond, and is grafted with a sulfydryl-containing sulphobetaine derivative through Michael addition; the cartilage anchoring and active oxygen removal are realized by utilizing phenylboronic acid groups, agglomeration is prevented by utilizing a sulphobetaine hydration layer, cells are protected by matching with trehalose, and the cartilage hydrogel has high dispersity, high survival rate and excellent tissue adhesion.

The present invention relates to a process for preparation of compositions comprising human umbilical cord blood plasma and a designed specific culture medium to grow these cells in specific conditions.The compositions of the present invention are rich in regenerative factors derived from mesenchymal stem cells and together with other designed culture medium factors and processes, are useful in tissue regeneration processes and for preservation, conservation and expansion of mesenchymal stem cells. In fact, the present invention allows a better therapeutic option compared to traditional cell transplantation, as it can benefit from the local tissue response to the secreted molecules without the difficulties and complications associated to the engraftment of the allo- or xeno-transplanted mesenchymal stem cells.Therefore, the present invention is in the field of cell-based therapies for skeletal disorders, such as joint disorders, disorders of connective tissue, bone diseases, osteoporosis, and other damaged tissues, and for modulating the inflammatory process related to tissue regeneration as well.

The invention relates to the technical field of medical health information, in particular to a case analysis and prediction method for secondary ear symptoms caused by maxillofacial joint disorder, and the method comprises the steps: obtaining original multi-modal data of a plurality of sample objects at different follow-up visit points; for each sample object, obtaining an individual feature value set under each follow-up visit point; performing multi-modal fusion processing according to the individual feature value set under each follow-up visit point, and determining a comprehensive state index of the sample object under each follow-up visit point; constructing an individual dynamic trajectory fitting curve according to the comprehensive state indexes of the sample object under all the follow-up visit points, and extracting a plurality of change feature values from the individual dynamic trajectory fitting curve; and obtaining the change characteristic values of all the sample objects as training input characteristic data of the analysis model. According to the method, multi-modal fusion analysis is carried out on individual feature values of different feature dimensions, so that the data quality and representativeness of the training data are effectively improved.

This article discloses a material composition and a method for using the composition to treat... For example Methods for treating cancer or inflammatory joint diseases. The composition is a soluble recombinant human flatfoot protein receptor (srhPDPN) comprising a first amino acid sequence at least 95% homologous to SEQ ID NO:1. The srhPDPN may comprise a tag peptide or polypeptide (such as a multihistidine tag) fused to the first amino acid sequence. The srhPDPN may comprise a signal peptide fused to the first amino acid sequence. The signal peptide may comprise an amino acid sequence at least 95% homologous to SEQ ID NO:2. Multiple threonine residues of the srhPDPN may be partially glycosylated with sialic acid, and in some embodiments, 17 threonine residues of the srhPDPN are partially glycosylated with sialic acid. Treatment may include allowing the composition to act as a decoy receptor or ligand trap to inhibit PDPN signaling.

1. The name of the design product: infrared physiotherapy lamp (L9). 2. The use of the design product: medical device for assisting the treatment of joint diseases of the user. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

A composition may have an adeno-associated virus (AAV) vector containing a nucleic acid sequence encoding NFAT1 (Nuclear Factor of Activated T Cells 1) protein for treatment of osteoarthritis and other joint diseases. The AAV vector may be AAV serotype 5, other AAV serotypes, and AAV subtype variants. The nucleic acid sequence encoding NFAT1 may be constitutively active NF ATI or wild-type NF ATI. The nucleic acid sequence encoding NFAT 1 may comprise a hemagglutinin epitope tag. At least one AAV vector may comprise a viral genome concentration of about 2x1010 viral genomes. The NFAT 1 may be human NFAT1. The NFAT1 may be mouse NFAT1. A pharmaceutical composition may comprise the composition and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be suitable for intra-articular or local tissue injection. The pharmaceutically acceptable carrier may be sterile saline.